The Experts below are selected from a list of 71691 Experts worldwide ranked by ideXlab platform
Sabine Bahn - One of the best experts on this subject based on the ideXlab platform.
-
Commercialisation of biomarker tests for mental illnesses advances and obstacles
Trends in Biotechnology, 2015Co-Authors: Man K Chan, Jason D. Cooper, Sabine BahnAbstract:Substantial strides have been made in the field of biomarker research for mental illnesses over the past few decades. However, no US FDA-cleared blood-based biomarker tests have been translated into routine clinical practice. Here, we review the challenges associated with Commercialisation of research findings and discuss how these challenges can impede scientific impact and progress. Overall evidence indicates that a lack of research funding and poor reproducibility of findings were the most important obstacles to commercialization of biomarker tests. Fraud, pre-analytical and analytical limitations, and inappropriate statistical analysis are major contributors to poor reproducibility. Increasingly, these issues are acknowledged and actions are being taken to improve data validity, raising the hope that robust biomarker tests will become available in the foreseeable future.
-
Commercialisation of Biomarker Tests for Mental Illnesses: Advances and Obstacles
Trends in Biotechnology, 2015Co-Authors: Man K Chan, Jason D. Cooper, Sabine BahnAbstract:Substantial strides have been made in the field of biomarker research for mental illnesses over the past few decades. However, no US FDA-cleared blood-based biomarker tests have been translated into routine clinical practice. Here, we review the challenges associated with Commercialisation of research findings and discuss how these challenges can impede scientific impact and progress. Overall evidence indicates that a lack of research funding and poor reproducibility of findings were the most important obstacles to commercialization of biomarker tests. Fraud, pre-analytical and analytical limitations, and inappropriate statistical analysis are major contributors to poor reproducibility. Increasingly, these issues are acknowledged and actions are being taken to improve data validity, raising the hope that robust biomarker tests will become available in the foreseeable future. Substantial advances have been made in the field of biomarker research for mental illnesses.However, no FDA-cleared blood-based biomarker tests have been translated into clinical applications.A personal account of challenges associated with Commercialisation of research findings is reported.The major obstacles and challenges encountered in the field are briefly discussed.
Jonathan Lewis - One of the best experts on this subject based on the ideXlab platform.
-
stationary fuel cells insights into Commercialisation
International Journal of Hydrogen Energy, 2014Co-Authors: Jonathan LewisAbstract:Abstract Stationary fuel cell systems have been under development for several decades and have been demonstrated for a number of years across Asia, Europe and North America. Commercialisation of these systems is now accelerating with small and large scale systems being installed worldwide. Successful Commercialisation requires a dual approach to identifying both early adopters in specific market segments whilst also seeking to reduce costs on a year on year basis. This paper provides an oversight of the current status of Commercialisation and explores the key cost and market segmentation challenges.
-
Stationary fuel cells – Insights into Commercialisation
International Journal of Hydrogen Energy, 2014Co-Authors: Jonathan LewisAbstract:Abstract Stationary fuel cell systems have been under development for several decades and have been demonstrated for a number of years across Asia, Europe and North America. Commercialisation of these systems is now accelerating with small and large scale systems being installed worldwide. Successful Commercialisation requires a dual approach to identifying both early adopters in specific market segments whilst also seeking to reduce costs on a year on year basis. This paper provides an oversight of the current status of Commercialisation and explores the key cost and market segmentation challenges.
-
Stationary fuel cells - Insights into Commercialisation
International Journal of Hydrogen Energy, 2014Co-Authors: Jonathan LewisAbstract:Stationary fuel cell systems have been under development for several decades and have been demonstrated for a number of years across Asia, Europe and North America. Commercialisation of these systems is now accelerating with small and large scale systems being installed worldwide. Successful Commercialisation requires a dual approach to identifying both early adopters in specific market segments whilst also seeking to reduce costs on a year on year basis. This paper provides an oversight of the current status of Commercialisation and explores the key cost and market segmentation challenges. © 2014 Hydrogen Energy Publications, LLC.
Hanna L. Hellman - One of the best experts on this subject based on the ideXlab platform.
-
characterising fuel cell technology challenges of the Commercialisation process
International Journal of Hydrogen Energy, 2007Co-Authors: Hanna L. Hellman, Robert Van Den HoedAbstract:The Commercialisation of a new technology is a challenging and uncertain process. Likewise, the emerging fuel cell (FC) industry experiences numerous technical and market uncertainties to shift from primarily Research and Development activities to activities in production, marketing and sales. This paper aims to gain a better understanding of the management challenges FC firms face in the current pre-Commercialisation phase. First, a brief literature review on technology Commercialisation is given. Second, a characterisation is made of (i) the technology, (ii) the market for FC products, (iii) the environment and (iv) the FC industry to highlight the key uncertainties and challenges of managing the Commercialisation of FC technology. In the final discussion this paper suggests that FC firms face dilemmas in decision-making, regarding resource acquisition, competence development, product development and niche market selection. This research may provide insight into the challenges of managing the Commercialisation of FC technology.
-
Characterising fuel cell technology: Challenges of the Commercialisation process
International Journal of Hydrogen Energy, 2007Co-Authors: Hanna L. Hellman, Robert Van Den HoedAbstract:The Commercialisation of a new technology is a challenging and uncertain process. Likewise, the emerging fuel cell (FC) industry experiences numerous technical and market uncertainties to shift from primarily Research and Development activities to activities in production, marketing and sales. This paper aims to gain a better understanding of the management challenges FC firms face in the current pre-Commercialisation phase. First, a brief literature review on technology Commercialisation is given. Second, a characterisation is made of (i) the technology, (ii) the market for FC products, (iii) the environment and (iv) the FC industry to highlight the key uncertainties and challenges of managing the Commercialisation of FC technology. In the final discussion this paper suggests that FC firms face dilemmas in decision-making, regarding resource acquisition, competence development, product development and niche market selection. This research may provide insight into the challenges of managing the Commercialisation of FC technology. © 2006 International Association for Hydrogen Energy.
Jarkko; Pellikka - One of the best experts on this subject based on the ideXlab platform.
-
Are Commercialisation process models beneficial for small technology firms
International Journal of Technology Transfer and Commercialisation, 2011Co-Authors: Jarkko; PellikkaAbstract:Commercialisation process models have been shown to be effective tools for controlling and monitoring the Commercialisation and thus realising the economic potential, of innovations in large firms. However, little is known about their potential benefits for small firms. Therefore, this study explores the perceived utility of Commercialisation process models for small technology-based firms, using information obtained from eight companies in the Kuopio region of Eastern Finland: four that utilise such models and four that do not. The results indicate that the models have helped the former group to overcome certain types of challenges associated with Commercialisation, including setting measurable objectives, defining decision-making criteria and managing resources during Commercialisation. The small technology-based firms that have used a Commercialisation process model have experienced fewer significant problems than the other case firms.
-
Problems of Commercialisation in Small Technology-based Firms
International Journal of Entrepreneurship and Innovation Management, 2009Co-Authors: Jarkko; Pellikka, Mikko VirtanenAbstract:Small Technology Firms (STFs) have an important role in revitalising economy since they contribute to employment and Commercialisation of innovations. STFs face several challenges during their Commercialisation process. The purpose of this study is to answer the following research questions: · How the problems of the Commercialisation process are described in former studies? · What problems do STFs confront during Commercialisation process? The problem areas of Commercialisation are: · infrastructure · marketing · financing · internationalisation. STF managers and venture capitalists should focus especially marketing and internationalisation. Policymakers and educators should ensure the availability of skilled resources for STFs. Copyright © 2009 Inderscience Enterprises Ltd.
-
Innovation support services and Commercialisation process of innovation in small technology firms
International Journal of Innovation and Regional Development, 2009Co-Authors: Jarkko; PellikkaAbstract:Commercialisation process of innovation is crucial among small technology firms particularly in a dynamic business environment. Particularly, small high technology firms are dependent on the regional system of innovation (RIS) and its ability to support and supplement the Commercialisation process through innovation support services (ISS). Therefore, it is essential to respond to their needs in terms of both the type of service and quality of delivery to develop the support mechanisms for the small technology firms. Using the multiple case study methodology, this research attempts to answer what kind of ISS small healthcare technology firms use during the Commercialisation process of innovation. In addition, this paper presents how these services should be developed and contributed in order to enhance the Commercialisation process of innovation. Results indicate that small technology firms are using different kind of ISS during their Commercialisation process of innovation. In addition, utilisation and the content of the ISS varying between the stages of the Commercialisation process. More attention should be paid for increase needs orientation of the process of delivering services and adaptation of innovation services to the respective stage of development of each business.
-
Problems of Commercialisation in Small Technology-based Firms
International Journal of Entrepreneurship and Innovation Management, 2009Co-Authors: Jarkko; Pellikka, Mikko VirtanenAbstract:Small Technology Firms (STFs) have an important role in revitalising economy since they contribute to employment and Commercialisation of innovations. STFs face several challenges during their Commercialisation process. The purpose of this study is to answer the following research questions: How the problems of the Commercialisation process are described in former studies? What problems do STFs confront during Commercialisation process? The problem areas of Commercialisation are: infrastructure; marketing; financing; internationalisation. STF managers and venture capitalists should focus especially marketing and internationalisation. Policymakers and educators should ensure the availability of skilled resources for STFs.
-
Fostering Commercialisation of innovation in small high technology firms
International Journal of Technoentrepreneurship, 2007Co-Authors: Jarkko; Pellikka, Jari LauronenAbstract:Based on their capability to commercialise innovations small technology-based firms serve as promoters of economical growth. However, to date the empirical research on the Commercialisation process in small high-tech firms has been relatively limited. This study describes the activities and the different phases that small- and medium-sized healthcare technology firms have conducted during the Commercialisation process of innovations. The results suggest that the balanced allocation of resources have a crucial role during the Commercialisation process. In addition, the development of collaboration with resellers and the exploitation of the Innovation Support Services (ISS) are essential in order to improve the effectiveness of the Commercialisation process of innovations. Intense collaboration may lead to shorter product life cycles and further enhances the firm's capability to adapt to/adjust to the increasing dynamics of the business environment.
Man K Chan - One of the best experts on this subject based on the ideXlab platform.
-
Commercialisation of biomarker tests for mental illnesses advances and obstacles
Trends in Biotechnology, 2015Co-Authors: Man K Chan, Jason D. Cooper, Sabine BahnAbstract:Substantial strides have been made in the field of biomarker research for mental illnesses over the past few decades. However, no US FDA-cleared blood-based biomarker tests have been translated into routine clinical practice. Here, we review the challenges associated with Commercialisation of research findings and discuss how these challenges can impede scientific impact and progress. Overall evidence indicates that a lack of research funding and poor reproducibility of findings were the most important obstacles to commercialization of biomarker tests. Fraud, pre-analytical and analytical limitations, and inappropriate statistical analysis are major contributors to poor reproducibility. Increasingly, these issues are acknowledged and actions are being taken to improve data validity, raising the hope that robust biomarker tests will become available in the foreseeable future.
-
Commercialisation of Biomarker Tests for Mental Illnesses: Advances and Obstacles
Trends in Biotechnology, 2015Co-Authors: Man K Chan, Jason D. Cooper, Sabine BahnAbstract:Substantial strides have been made in the field of biomarker research for mental illnesses over the past few decades. However, no US FDA-cleared blood-based biomarker tests have been translated into routine clinical practice. Here, we review the challenges associated with Commercialisation of research findings and discuss how these challenges can impede scientific impact and progress. Overall evidence indicates that a lack of research funding and poor reproducibility of findings were the most important obstacles to commercialization of biomarker tests. Fraud, pre-analytical and analytical limitations, and inappropriate statistical analysis are major contributors to poor reproducibility. Increasingly, these issues are acknowledged and actions are being taken to improve data validity, raising the hope that robust biomarker tests will become available in the foreseeable future. Substantial advances have been made in the field of biomarker research for mental illnesses.However, no FDA-cleared blood-based biomarker tests have been translated into clinical applications.A personal account of challenges associated with Commercialisation of research findings is reported.The major obstacles and challenges encountered in the field are briefly discussed.
